Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency
| Autor: | Gary R. Albert, Joseph M. Parker, John E. Moran, Brandon M. Hardesty, Pierre Laurin, Neelam Thukral, Per Morten Sandset, Charles Nakar, Karen Thibaudeau, Amy D. Shapiro |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Conjunctiva Adolescent Immunology 030204 cardiovascular system & hematology Biochemistry Gastroenterology 03 medical and health sciences 0302 clinical medicine Blood Coagulation Disorders Inherited Internal medicine medicine Clinical endpoint Humans Child Cervix Aged Aged 80 and over Bronchus Kidney business.industry Therapeutic effect Plasminogen Cell Biology Hematology Middle Aged Clinical trial medicine.anatomical_structure 030220 oncology & carcinogenesis Child Preschool Vagina Female business |
| Zdroj: | Blood. 131(12) |
| ISSN: | 1528-0020 |
| Popis: | Congenital plasminogen deficiency is caused by mutations in PLG, the gene coding for production of the zymogen plasminogen, and is an ultrarare disorder associated with abnormal accumulation or growth of fibrin-rich pseudomembranous lesions on mucous membranes. Left untreated, these lesions may impair organ function and impact quality of life. Plasminogen replacement therapy should provide an effective treatment of the manifestations of congenital plasminogen deficiency. An open-label phase 2/3 study of human Glu-plasminogen administered IV at 6.6 mg/kg every 2 to 4 days in 15 patients with congenital plasminogen deficiency is ongoing. Reported here are data on 14 patients who completed at least 12 weeks of treatment. The primary end point was an increase in trough plasminogen activity levels by at least an absolute 10% above baseline. The secondary end point was clinical success, defined as ≥50% improvement in lesion number/size or functionality impact from baseline. All patients achieved at least an absolute 10% increase in trough plasminogen activity above baseline. Clinical success was observed in all patients with clinically visible (conjunctiva and gingiva), nonvisible (nasopharynx, bronchus, colon, kidney, cervix, and vagina), and wound-healing manifestations of the disease. Therapeutic effects were rapid, as all but 2 lesions resolved or improved after 4 weeks of treatment. Human Glu-plasminogen was well tolerated in both children and adults. This study provides critical first evidence of the clinical utility of ongoing replacement therapy with human Glu-plasminogen for the treatment of children and adults with congenital plasminogen deficiency. This trial was registered at www.clinicaltrials.gov as #NCT02690714. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|